<DOC>
	<DOCNO>NCT00387647</DOCNO>
	<brief_summary>The purpose study find patient old 60 , acute myeloid leukemia , complete remission follow initial chemotherapy , live long low rate leukemia relapse treat azacitidine .</brief_summary>
	<brief_title>Maintenance Azacitidine Elderly Patients With Acute Myeloid Leukemia ( AML ) CR After Induction Chemotherapy</brief_title>
	<detailed_description>Patient activity encompass approximately 48 month : approximate 24 month enrollment period , follow 6 12 month patient treatment . Patients follow 1 year follow completion study drug treatment . During follow-up , bone marrow biopsy confirm disease status obtain peripheral blood blast present development unexpected blood abnormality warrant suspicion relapse , minimum every 6 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Histologic cytologic confirmation AML great 20 % blast bone marrow . All AML subtypes World Health Organization ( WHO ) classification include exception promyelocytic leukemia cytogenetics show ( 15 ; 17 ) translocation AML secondary chemotherapy . Achieved first morphologic complete remission ( CR ) first morphologic complete remission incomplete platelet recovery ( CRp ) completion induction chemotherapy use standard induction regimen . Up 2 induction cycle allow . Confirmation CR define &lt; 5 % blast bone marrow specimen , count least 100200 nucleated cell absence Auer rod , along peripheral blood neutrophil count &gt; 1.0 x 10^9/L platelet count &gt; 100 x 10^9/L . Confirmation CRp define &lt; 5 % blast bone marrow specimen , count least 100200 nucleated cell absence Auer rod , incomplete platelet recovery ( ANC ≥ 1000/µL platelet 5099,000/µL , along transfusionindependence red blood cell ) . Received 2 cycle consolidation chemotherapy Have Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 Normal organ function time screening : Total bilirubin ≤1.5 x upper limit normal ( ULN ) ; aspartic transaminase ( AST ) alanine transaminase ( ALT ) ≤2.5 x ULN ; Serum creatinine ≤1.5 x ULN creatinine clearance &gt; 60 mL/min patient creatinine level ULN Men must agree avoid father child throughout study . Be capable give informed consent sign informed consent form ( ICF ) Greater 12 week since initiation recent cycle consolidation chemotherapy Women childbearing potential Prior relapse complete remission AML AML secondary previous exposure cytotoxic chemotherapy know induce leukemia Active malignancy AML Any diagnosis metastatic disease Have hepatic tumor Radiation therapy , chemotherapy , cytotoxic therapy , give treat condition AML &lt; 4 week prior Day 1 recover adverse event due agent administer &gt; 4 week earlier Known leukemic involvement central nervous system Known suspect hypersensitivity azacitidine mannitol Prior active disease , opinion Investigator , may interfere procedure evaluation conduct study ( uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement ) Active viral infection know human immunodeficiency virus ( HIV ) viral hepatitis type B C Treatment investigational drug within 30 day prior Day 1 , ongoing adverse event previous treatment investigational drug , regardless time period Any prior treatment azacitidine decitabine</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>myeloid</keyword>
	<keyword>acute</keyword>
	<keyword>monocytic</keyword>
</DOC>